Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass

J Clin Pharm Ther. 2017 Oct;42(5):624-626. doi: 10.1111/jcpt.12547. Epub 2017 May 5.

Abstract

What is known and objective: The impact of gastric bypass surgery on the pharmacokinetics of various medications has been reported. Presently, no data exist for the treatment of chronic hepatitis C virus with ledipasvir/sofosbuvir (LDV/SOF) in an individual with a history of gastric bypass.

Case description: We report the successful cure of an individual who was treated with LDV/SOF who had a history of gastric bypass. The patient tolerated LDV/SOF well while only experiencing a minor headache.

What is new and conclusion: Ledipasvir/sofosbuvir treatment may still be effective in those with a history of gastric bypass surgery.

Keywords: LDV/SOF; harvoni; hepatitis C virus; ledipasvir/sofosbuvir.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Drug Combinations
  • Female
  • Fluorenes / adverse effects
  • Fluorenes / therapeutic use*
  • Gastric Bypass*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Sofosbuvir
  • Treatment Outcome
  • Uridine Monophosphate / adverse effects
  • Uridine Monophosphate / analogs & derivatives*
  • Uridine Monophosphate / therapeutic use

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Drug Combinations
  • Fluorenes
  • ledipasvir, sofosbuvir drug combination
  • Uridine Monophosphate
  • Sofosbuvir